Carbapenemase-producing bacteria are mostly Enterobacteriaceae (carbapenemase-producing Enterobacteriaceae \[CPE\]), *Pseudomonas aeruginosa*, and *Acinetobacter* species ([@R1], [@R2]); and over the last decade, CPE have been reported with increasing frequency in all parts of the world. *Klebsiella pneumoniae* carbapenemase (KPC) producers were first described in the United States, and endemicity in hospitals has been established in many countries ([@R3]--[@R5]). Metallo-β-lactamase (MBL)-producing CPE are endemic in large regions of Asia or some parts of Southern Europe, and have been reported worldwide, often owing to international travel ([@R4]). CPE with OXA-48 type carbapenemases have been identified mostly in east and south Mediterranean countries, India, and all over Europe upon transfers from endemic regions ([@R4]).

CPE pose major challenges in patient management. Resistance is not consistently phenotypically expressed, hampering identification by routine microbiological laboratory methods ([@R1], [@R6], [@R7]). Failure to aggressively implement infection control measures has lagged behind the spread of CPE, and there are limited options for effective antibiotic treatment of infections ([@R7]--[@R9]). Several factors have been associated with increased risks of acquisition of CPE or carbapenem-resistant Enterobacteriaceae such as prior exposure to antibiotics, age, and severe illness ([@R10]--[@R12]).

Infections caused by CPE, mainly bloodstream infections by *K. pneumoniae*, have been associated with increased mortality as compared with infections caused by Enterobacteriaceae susceptible to carbapenems ([@R10]--[@R12]), with in-hospital mortality of carbapenem-resistant *K. pneumoniae* (CRKP) infections ranging between 27% and 61% ([@R10], [@R12]--[@R16]). Colonization precedes infection in most instances, and it, therefore, is a marker of a patient being at risk of a poorer outcome. Colonization with multidrug-resistant Gram-negative bacteria (e.g., *Acinetobacter* species, *P. aeruginosa*, and extended-spectrum β-lactamase-producing Enterobacteriaceae) has been associated with an increased risk of death of ICU patients ([@R17], [@R18]), and we wish to examine this relationship within the context of CPE endemicity.

MATERIALS AND METHODS
=====================

Study Design and Participants
-----------------------------

We conducted a post hoc analysis of data from two Greek ICUs (Attikon University Hospital and Laikon General Hospital), that participated in an international interrupted time series and cluster randomized controlled trial, in which different infection control interventions were evaluated ([@R8]). These interventions were not associated with statistically significant effects on acquisition of highly resistant Enterobacteriaceae. A waiver for informed consent was granted for all participating centers in this trial by the institution's review board or national ethics committee. Patients 18 years old or older admitted to the ICU with an expected length of stay (LOS) of 3 days or longer were included in the current study. Patients in the current study were included between August 2008 and January 2011. Patient characteristics were recorded at time of admission. Disposition at ICU discharge was defined as either deceased or alive.

Microbiology
------------

Swabs from perineum and wounds (if present) were obtained within 2 days of admission and twice weekly thereafter. Culture frequency was reduced to once per week in patients staying longer than 3 weeks. All swabs were analyzed in the local laboratory according to a standardized protocol. Swabs were plated onto the Brilliance ESBL 2 Agar and colonies from the groups of *Escherichia coli*, *Klebsiella*/*Enterobacter*/*Serratia*/*Citrobacter*, and *Proteus*/*Providencia*/*Morganella* were selected ([@R8]). One colony of each morphotype per patient was selected for further analysis, and shipped to a central laboratory. Species identification was done with the Vitek 2 system (bioMérieux, Marcy l'Etoile, France). Isolates with nonsusceptibility to at least one of the carbapenems ertapenem, imipenem, and meropenem according to European Committee on Antimicrobial Susceptibility Testing criteria (<http://www.eucast.org>) were subjected to phenotypic detection of MBLs (double disk synergy test with disks containing imipenem, ceftazidime, and EDTA), KPCs (combined-disk test with disks containing imipenem and meropenem, and both supplemented with phenylboronic acid), and OXA-48 (temocillin disk test) ([@R6], [@R19], [@R20]). All of the isolates with phenotypes indicative of being CPE were subjected to polymerase chain reactions specific for *bla*~KPC~-, *bla*~IMP~-, *bla*~VIM~-, *bla*~NDM~-, and *bla*~OXA-48~-like genes ([@R21]--[@R24]).

Definitions
-----------

A patient was defined as being CPE colonized, if the patient had at least one CPE positive culture during ICU stay. The patient was assumed to have colonization at admission if the first culture was positive with CPE, and in analyses patients were assumed to be colonized from the date of admission. Colonization was considered acquired in case of a positive culture preceded by a negative one, and start of colonization was assumed to be in-between the last negative culture and the first positive culture. It was assumed that colonized patients remained colonized until death or discharge.

Statistical Analyses
--------------------

The association between CPE carriage and ICU mortality was investigated by competing risk models with CPE colonization as a time-dependent covariate ([@R25], [@R26]). Patients admitted to ICU either die or are discharged alive after a period of ICU stay. Discharged patients are usually in a better health condition than patients in ICU. Therefore, discharge should not be treated as censored, and it is recommended to treat it as a competing event for ICU mortality ([@R27]). Further, admitted patients may be colonized with CPE at admission, or acquire CPE carriage during ICU stay. In case of acquisition of colonization, patients have an additional transient state before discharge, corresponding to a time-dependent binary covariate (CPE colonization). Not taking timing of the colonization into account would cause time-dependent bias, causing artificial inflation of a protective effect, or dampening or even reversal of a harmful effect ([@R26], [@R28], [@R29]).

Cause-specific hazard ratios (CSHRs) for ICU death and discharge alive were analyzed in multivariable analysis to estimate the direct effects of CPE colonization and other characteristics, and subdistribution hazard ratios (SHRs) to assess the overall effects on ICU mortality ([@R26]). CPE colonization was included as a time-varying covariate in these analyses. Results are presented graphically in cause-specific cumulative hazard plots, as CPE colonization is modeled as a time-varying risk factor, and cumulative incidence functions cannot be interpreted for time-varying risk factors ([@R25]).

To investigate the assumption that acquired colonization starts halfway between the last negative and first positive culture, we performed sensitivity analyses using the first and the last possible moments of CPE colonization, being just after the last negative culture and just before the first positive culture respectively, resembling a best and a worst-case scenario. In both scenarios, patients colonized at admission were considered to be colonized from day 1.

A post hoc analysis was performed to investigate possible differences between the effect of KPC and MBL on ICU mortality, using two dichotomous variables and their interaction (for patients colonized with both carbapenemases) in the models described above (CSHRs and SHRs). To investigate generalizability of the results, a post hoc analysis was performed for both ICUs separately.

Analyses were performed using R version 2.15.1 (The R Foundation for Statistical Computing; [www.r-project.org/](www.r-project.org/)), using the survival package for CSHRs and SHRs, the mvna package for the cumulative hazard plots, and the clos function of the etm package for calculation of extra LOS, and *p* values less than 0.05 were considered statistically significant.

RESULTS
=======

A total of 1,007 patients with an expected LOS greater than or equal to 3 days and culture results available were included, of whom 36 (3.6%) were colonized with CPE at admission, 96 (9.5%) acquired colonization during their ICU stay, and 301 (29.9%) died in ICU (**Fig. [1](#F1){ref-type="fig"}**). Missed cultures more often occurred at the beginning or the end of study periods (so most likely independent of patient characteristics), and patients with a short length of ICU stay were more likely to be excluded because of missed cultures. These patients were typically more often surgical patients, with lower Acute Physiology and Chronic Health Evaluation (APACHE) II scores, and lower mortality (21%). Admission swabs were correctly taken in 93.5% of included patients, and 90.4% and 96.3% of included patients had a culture within 4 and 7 days before discharge (death or alive), respectively (for patients staying longer than 3 wk culture frequency was weekly according to protocol).

![Inclusion of patients, patient selection, and outcomes. CPE = carbapenemase-producing Enterobacteriaceae, LOS = length of stay, *n* = number of patients.](ccm-43-1170-g001){#F1}

There were 132 CPE isolates, of which 125 (94.7%) were *K. pneumoniae*, others were *Citrobacter freundii*, *Enterobacter cloacae*, *E. coli*, *Enterobacter* species other than *E. cloacae*, *Proteus mirabilis*, and *Providencia stuartii* (**Table [1](#T1){ref-type="table"}**). In 74 (56.1%) isolates KPC was present, in 54 (40.9%) isolates VIM type carbapenemases, and 4 (3.0%) isolates harbored both KPC and Verona integron-encoded metallo-β-lactamase (Table [1](#T1){ref-type="table"}). No OXA-48 was detected. Mean age of included patients was 63.7 years, 58.7% was male, and mean APACHE II score was 15.9 (**Table [2](#T2){ref-type="table"}**).

###### 

Bacterial Species and Carbapenemase Genotypes
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###### 

Descriptive Results of Potential Risk Factors and Outcomes

![](ccm-43-1170-g003)

In multivariable analysis, female gender, APACHE II score, presence of solid tumor, hematopoietic malignancy, chronic hepatic failure, and immunodeficiency significantly increased the CSHR for dying in ICU. There was no statistically significant difference between CPE colonized and uncolonized patients in CSHR for death (CSHR = 1.02; 95% CI, 0.74--1.41), so the daily hazard of dying was not increased for CPE colonized patients. However, CPE colonization was associated with a statistically significant reduction in the CSHR for being discharged alive (CSHR = 0.73; 95% CI, 0.51--0.94) (**Table [3](#T3){ref-type="table"}**), so the daily hazard of being discharged alive was lower for CPE colonized patients, leading to a longer LOS after being colonized with CPE, compared with patients that were not colonized with CPE. For some of the covariates in the cause-specific hazard analyses the proportionality assumption was violated, as happens often ([@R26], [@R30]), and these estimates should, therefore, be interpreted as the weighted average over follow-up. However, allowing the effects of the covariates to change over time did not change the estimate for CPE colonization.

###### 

Multivariable Analysis of Cause-Specific Hazard Ratios for ICU Mortality and Discharge Alive From ICU, With Carbapenemase-Producing Enterobacteriaceae Colonization as a Time-Dependent Covariate
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Six variables were associated with a statistically significant increase of the SHR for ICU mortality: CPE colonization (SHR = 1.79; 95% CI, 1.31--2.43), female gender (SHR = 1.28; 95% CI, 1.02--1.62), APACHE II score (SHR = 1.13; 95% CI, 1.11--1.15), presence of solid tumor (SHR = 1.54; 95% CI, 1.15--2.06), hematopoietic malignancy (SHR = 1.62; 95% CI, 1.04--2.51), and immunodeficiency (SHR = 1.59; 95% CI, 1.11--2.27) (**Table [4](#T4){ref-type="table"}**). This reflects an overall increase in mortality for patients colonized with CPE, taking into account the competing event of being discharged alive. The computed unadjusted expected change in LOS for CPE colonization was 3.2 days (95% CI, 2.1--4.3 d).

###### 

Multivariable Analysis of Subdistribution Hazard Ratios for ICU Mortality, With Carbapenemase-Producing Enterobacteriaceae Colonization as a Time-Dependent Covariate

![](ccm-43-1170-g005)

In sensitivity analyses, in which either the day of the last negative culture or the day of the first day positive culture were used as proxy for the start of colonization, similar results were found, with point estimates for the SHR of death of 1.67 (95% CI, 1.23--2.27) and 1.95 (95% CI, 1.43--2.66) for the first and last possible moment of colonization, respectively.

The observed effects of CPE carriage were comparable for KPC and MBL (SHR KPC = 1.65; 95% CI, 1.11--2.46; SHR MBL = 2.00; 95% CI, 1.30--3.07; interaction term nonsignificant). In separate analyses for both ICUs, SHR with overlapping CIs were found (odds ratio \[OR\], 2.12 \[95% CI, 1.28--3.51\] and 1.46 \[95% CI, 0.90--2.35\]).

DISCUSSION
==========

In this study, performed in two Greek ICUs with CPE endemicity, CPE colonization was associated with a 1.79 times higher overall hazard of mortality in ICU, which was caused by an increased LOS in ICU. Other independent risk factors that were associated with increased ICU mortality in multivariable subdistribution analysis were female gender, APACHE II score at ICU admission, presence of solid tumor, hematologic malignancy, and immunodeficiency.

The crude association between CPE colonization and death (40.9% mortality in CPE colonized vs 28.2% in uncolonized patients) was explored in the competing events multivariate analysis which incorporated potential confounding factors such as severity scores and comorbidities. The CSHRs for ICU death and discharge alive from ICU can be interpreted as two independent standard survival analyses disregarding the fact that they are related to each other. The CSHR for ICU death was not increased for patients colonized with CPE, implying that the daily risk of dying was not increased for CPE colonized patients. However, the CSHR for discharge alive was decreased for patients colonized with CPE, implying that colonized patients had a lower daily probability of being discharged alive from ICU after colonization. This resulted in a longer exposure to the daily risk of dying, thus increasing the total cumulative risk of dying in ICU. This was confirmed in the SHR that does take into account the competing event of being discharged alive, which revealed a significant increase in ICU death for CPE colonized patients. From the CSHRs, it can be concluded that the increased risk of dying in ICU is the result of a longer LOS in ICU after acquiring colonization. This is also illustrated in the cumulative hazard plots (**Fig. [2](#F2){ref-type="fig"}**). These results are in line with the calculated -- however unadjusted -- expected change in LOS of 3.2 days.

![Cause-specific cumulative hazard of ICU mortality, being discharged alive, colonized versus not colonized. Patients acquiring colonization during their hospital stay contribute the not carbapenemase-producing Enterobacteriaceae (CPE) colonized curve up to the moment of colonization acquisition, after which they switch to the CPE colonized curve.](ccm-43-1170-g006){#F2}

Results were comparable for both ICUs, suggesting the detected effect of CPE colonization is generalizable to other settings with CPE endemicity. Aggressiveness of therapy and chosen regimens may depend on CPE prevalence, so effects of CPE colonization may be different in low endemic settings.

In contrast to other studies that focused on infections caused by CPE, we investigated the effects of colonization, irrespective if it was associated with infection or not. It is still uncertain (though easy imaginable) that mortality can be attributed to CPE infections, as some studies investigating the effect of infection with CRKP compared with carbapenem susceptible *Klebsiella pneumoniae* on in-hospital mortality, not specifically focusing on ICU patients, reported statistically significant ([@R10], [@R12], [@R15]) or absence of differences in mortality ([@R13]). In a prospective observational study of 226 ICU patients ([@R31]) in a setting of high KPC endemicity, mortality was---in univariate analysis---not significantly higher in KPC-producing *K. pneumoniae* (KPC-Kp) colonized patients compared with KPC-Kp-negative patients (38.4 vs 27.4%; *p* = 0.160), but length of ICU stay was (25.8 d for KPC-Kp-positive and 12.8 d for KPC-Kp-negative patients; *p* \< 0.001). In multivariate analysis, KPC-Kp colonization was not an independent risk factor for mortality, however, KPC-Kp infection was an independent risk factor (OR, 2.8; 95% CI, 1.1--6.9). In another study, both ICU and in-hospital mortality rates did not differ significantly between patients that acquired CRKP in ICU and CRKP-noncolonized patients, but the length of ICU stay was significantly longer for patients acquiring CRKP colonization (24.8 vs 13.7 d; *p* \< 0.0001) ([@R32]). Yet, not accounting competing events and time-dependent covariates may have introduced bias in both studies.

APACHE II score at ICU admission was an independent risk factor for ICU mortality. The effect of CPE colonization on ICU mortality is adjusted for this effect. The association between female gender and ICU mortality has been reported before, but not consistently ([@R33]--[@R37]).

This study has several limitations, for instance because some assumptions were needed in our analyses. The exact moment of CPE colonization was unknown, as cultures were taken twice weekly. We assumed colonization to occur midway between the last negative and first positive culture. However, sensitivity analyses using the first or the last possible moment of colonization as time of colonization gave similar results, strengthening the validity of this assumption. Compliance to microbiological culture protocol was high, minimizing the risk of bias. Further, we assumed that CPE colonized patients remain colonized until the end of ICU stay. As there were no attempts for decolonization we consider this a valid assumption.

The use of ESBL-selective chromogenic medium may have induced missing ESBL-negative OXA-48 isolates. Yet, no ESBL and OXA-48 coproducing isolates were detected, thus the probability of missing significant amounts of colonized patients seems low. The first reported OXA-48 outbreak in Greece occurred between December 2011 and March 2012, which was after the current study ([@R38]).

Finally, the potential confounders that could be adjusted for was restricted, and did not include time-varying confounders, such as disease severity scores. Additionally, all-cause mortality could have been confounded by diagnosis at ICU admission and more specifically defined underlying comorbidities. Therefore, residual confounding may still be present. Additionally, we did not assess antibiotic use. Although results of screening for CPE were not known to treating physicians, patients with clinical cultures with CPE might have been treated with antibiotics for this, influencing chances of dying or discharge alive. Furthermore, we could not explore whether patients who were colonized by CPE developed an infection and if they died due to that infection.
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